Fulcrum Therapeutics discontinues its pociredir program after the Food and Drug Administration raises concerns.

By Siddhi Mahatole June 2 (Reuters) - Shares of Fulcrum Therapeutics plunged 52% on Tuesday after the company said it would ...

Fulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, ...

Stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults when compared ...

June 1 (Reuters) - Fulcrum Therapeutics said on Monday it would stop developing its experimental sickle-cell disease drug after the U.S. Food and Drug Administration raised cancer-risk concerns, which ...

Afimmune Reports Positive Phase 2 Results for Epeleuton in Sickle Cell Disease, Reducing Vaso-Occlusive Crisis Rate by ...

(Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for severe diseases ...

In its strategic review, Fulcrum said it will consider alternatives including mergers, acquisitions or other strategic transactions involving the company and its assets. The company has also ...

The Foundation for Sickle Cell Disease Research (FSCDR) welcomes critically revered, award-winning actress, producer, ...

Sickle Cell Disease (SCD) is a genetic blood disorder that affects millions globally, especially in India's tribal and rural populations. According to the World Health Organisation (WHO), it is one of ...